Matthew Harrison
Stock Analyst at Morgan Stanley
(3.34)
# 961
Out of 4,225 analysts
470
Total ratings
45.97%
Success rate
1.14%
Average return
Main Sectors:
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Overweight | $34 → $32 | $17.31 | +84.86% | 11 | Nov 14, 2023 | |
| BIIB Biogen | Maintains: Overweight | $361 → $373 | $232.06 | +60.73% | 32 | Nov 10, 2023 | |
| GMAB Genmab | Maintains: Underweight | $33 → $32 | $31.28 | +2.30% | 19 | Nov 9, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $359 → $364 | $351.00 | +3.70% | 14 | Nov 8, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Overweight | $55 → $38 | $10.61 | +258.15% | 3 | Nov 7, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $915 → $914 | $808.59 | +13.04% | 8 | Nov 3, 2023 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Overweight | $42 → $38 | $25.35 | +49.90% | 6 | Nov 2, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $125 → $117 | $89.74 | +30.38% | 16 | Nov 2, 2023 | |
| ARGX argenx SE | Maintains: Overweight | $604 → $607 | $435.92 | +39.25% | 11 | Nov 1, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $183 → $146 | $80.40 | +81.59% | 26 | Oct 31, 2023 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Equal-Weight | $4 → $8 | $5.92 | +35.14% | 8 | Oct 26, 2023 | |
| BGNE BeiGene | Maintains: Overweight | $321 → $319 | $183.13 | +74.19% | 14 | Aug 29, 2023 | |
| IOBT IO Biotech | Maintains: Overweight | $11 → $7 | $1.22 | +473.77% | 3 | Aug 15, 2023 | |
| PRME Prime Medicine | Maintains: Equal-Weight | $21 → $19 | $7.17 | +164.99% | 3 | Aug 14, 2023 | |
| TNYA Tenaya Therapeutics | Maintains: Overweight | $13 → $14 | $1.86 | +652.69% | 4 | Aug 10, 2023 | |
| ALEC Alector | Reiterates: Equal-Weight | $10 | $5.43 | +84.16% | 6 | Aug 7, 2023 | |
| MRNA Moderna | Maintains: Equal-Weight | $128 → $123 | $79.01 | +55.68% | 19 | Aug 4, 2023 | |
| INSM Insmed | Reiterates: Overweight | $41 | $25.10 | +63.35% | 7 | Aug 4, 2023 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $86 → $88 | $75.23 | +16.97% | 23 | Aug 4, 2023 | |
| TSVT 2seventy bio | Downgrades: Equal-Weight | $25 → $13 | $1.92 | +577.08% | 8 | Jul 28, 2023 | |
| LEGN Legend Biotech | Maintains: Overweight | $65 → $85 | $59.82 | +42.09% | 8 | Jul 20, 2023 | |
| BLUE bluebird bio | Reiterates: Underweight | $3 | $3.86 | -22.28% | 17 | Jul 11, 2023 | |
| CMCSA Comcast | Reiterates: Buy | $46 | $41.63 | +10.50% | 1 | Apr 24, 2023 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $61 → $63 | $18.39 | +242.58% | 8 | Apr 12, 2023 | |
| VIGL Vigil Neuroscience | Maintains: Equal-Weight | $12 → $13 | $3.20 | +306.25% | 4 | Mar 27, 2023 | |
| IVVD Invivyd | Maintains: Underweight | $2 → $1 | $1.52 | -34.21% | 3 | Mar 27, 2023 | |
| INVA Innoviva | Maintains: Underweight | $13 → $10 | $13.69 | -26.95% | 8 | Mar 3, 2023 | |
| FULC Fulcrum Therapeutics | Downgrades: Equal-Weight | $27 → $8 | $4.80 | +66.67% | 8 | Feb 28, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $57 → $44 | $36.96 | +19.05% | 16 | Feb 27, 2023 | |
| FUSN Fusion Pharmaceuticals | Maintains: Overweight | $19 → $10 | $4.77 | +109.64% | 3 | Jan 27, 2023 | |
| SANA Sana Biotechnology | Maintains: Overweight | $15 → $13 | $4.19 | +210.26% | 3 | Jan 24, 2023 | |
| LYEL Lyell Immunopharma | Maintains: Equal-Weight | $7 → $4 | $1.67 | +139.52% | 4 | Jan 24, 2023 | |
| EDIT Editas Medicine | Maintains: Underweight | $8 → $7 | $10.61 | -34.02% | 10 | Jan 24, 2023 | |
| BOLT Bolt Biotherapeutics | Maintains: Equal-Weight | $5 → $3 | $0.89 | +235.80% | 4 | Jan 24, 2023 | |
| BNTX BioNTech SE | Maintains: Equal-Weight | $203 → $216 | $99.25 | +117.63% | 8 | Jan 24, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Underweight | $7 → $4 | $2.95 | +35.59% | 7 | Jan 24, 2023 | |
| ADCT ADC Therapeutics | Maintains: Equal-Weight | $7 → $5 | $0.77 | +549.35% | 8 | Jan 24, 2023 | |
| ABBV AbbVie | Maintains: Overweight | $178 → $182 | $138.50 | +31.41% | 7 | Dec 6, 2022 | |
| KOD Kodiak Sciences | Maintains: Equal-Weight | $12 → $9 | $2.49 | +261.45% | 9 | Nov 14, 2022 | |
| AKRO Akero Therapeutics | Maintains: Equal-Weight | $30 → $40 | $16.66 | +140.10% | 5 | Nov 7, 2022 | |
| AMGN Amgen | Maintains: Overweight | $279 → $282 | $266.60 | +5.78% | 20 | Nov 4, 2022 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $220 → $210 | $164.01 | +28.04% | 7 | Oct 28, 2022 | |
| ALVR AlloVir | Maintains: Overweight | $32 → $27 | $1.78 | +1,416.85% | 5 | Sep 9, 2022 | |
| PFE Pfizer | Maintains: Equal-Weight | $55 → $52 | $30.08 | +72.87% | 5 | May 4, 2022 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $175 → $173 | $152.11 | +13.73% | 3 | Apr 6, 2022 | |
| SAGE Sage Therapeutics | Maintains: Equal-Weight | $61 → $57 | $19.48 | +192.61% | 4 | Mar 10, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $156 → $120 | $39.11 | +206.83% | 5 | Feb 1, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Equal-Weight | $145 → $148 | $32.11 | +360.92% | 9 | Jan 7, 2022 | |
| MRK Merck & Co. | Maintains: Equal-Weight | n/a | $101.13 | - | 4 | Nov 29, 2021 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | n/a | $48.72 | - | 2 | Oct 12, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | n/a | $1.82 | - | 2 | Aug 18, 2021 | |
| RPRX Royalty Pharma | Maintains: Equal-Weight | n/a | $26.90 | - | 1 | Aug 16, 2021 | |
| OGN Organon & Co. | Maintains: Equal-Weight | n/a | $11.41 | - | 1 | Aug 16, 2021 | |
| LLY Eli Lilly | Maintains: Overweight | n/a | $591.86 | - | 1 | Aug 4, 2021 | |
| TV Grupo Televisa, S.A.B. | Initiates: Buy | n/a | $2.88 | - | 1 | Jun 24, 2021 | |
| FRLN Freeline Therapeutics Holdings | Maintains: Overweight | n/a | $6.34 | - | 1 | Apr 6, 2021 | |
| RGNX REGENXBIO | Maintains: Overweight | n/a | $18.61 | - | 4 | Mar 8, 2021 | |
| HBAN Huntington Bancshares | Maintains: Equal-Weight | n/a | $11.13 | - | 1 | Feb 24, 2021 | |
| UBX Unity Biotechnology | Downgrades: Equal-Weight | n/a | $1.94 | - | 2 | Aug 18, 2020 | |
| EVLO Evelo Biosciences | Downgrades: Equal-Weight | n/a | $0.41 | - | 1 | May 21, 2020 | |
| INCY Incyte | Maintains: Equal-Weight | n/a | $53.39 | - | 1 | Jan 6, 2020 | |
| RDUS Schnitzer Steel Industries | Maintains: Overweight | n/a | $25.39 | - | 4 | Oct 11, 2018 | |
| CYTK Cytokinetics | Assumes: Equal-Weight | n/a | $32.14 | - | 4 | Sep 10, 2018 |